Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APGE |
---|---|---|
09:32 ET | 1501 | 50.25 |
09:34 ET | 3111 | 50.3 |
09:36 ET | 100 | 50.35 |
09:38 ET | 422 | 50.41 |
09:39 ET | 2276 | 50.86 |
09:43 ET | 892 | 50.98 |
09:45 ET | 200 | 51 |
09:48 ET | 100 | 50.915 |
09:50 ET | 1075 | 51.45 |
09:52 ET | 7170 | 51.135 |
09:54 ET | 100 | 50.99 |
09:56 ET | 200 | 51.115 |
09:57 ET | 100 | 51.11 |
09:59 ET | 400 | 51.13 |
10:01 ET | 900 | 51.4 |
10:03 ET | 1100 | 51.07 |
10:06 ET | 400 | 50.9 |
10:08 ET | 250 | 50.815 |
10:10 ET | 300 | 50.81 |
10:12 ET | 700 | 50.765 |
10:14 ET | 1440 | 51.03 |
10:15 ET | 300 | 51.25 |
10:19 ET | 100 | 51.06 |
10:21 ET | 200 | 51.32 |
10:24 ET | 121 | 51.39 |
10:32 ET | 1000 | 51.41 |
10:33 ET | 504 | 51.49 |
10:35 ET | 1966 | 51.83 |
10:37 ET | 200 | 51.675 |
10:39 ET | 2440 | 51.45 |
10:42 ET | 400 | 51.49 |
10:44 ET | 100 | 51.34 |
10:46 ET | 900 | 51.07 |
10:48 ET | 400 | 51.01 |
10:50 ET | 600 | 50.895 |
10:51 ET | 6580 | 51.36 |
10:55 ET | 100 | 51.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Apogee Therapeutics Inc | 2.9B | -25.1x | --- |
Geron Corp | 2.9B | -14.5x | --- |
Morphic Holding Inc | 2.8B | -16.0x | --- |
MoonLake Immunotherapeutics | 3.1B | -65.3x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.1x | --- |
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.04 |
Book Value | $7.86 |
P/E Ratio | -25.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.